| Today’s Big NewsSep 6, 2024 |
|
Who’s Leading the Way in Clinical Research? Nominate Them for the CRO Awards! The Fierce CRO Awards shine a spotlight on the organizations that are setting new standards in clinical research and development. If your CRO excels in innovation, quality, and leadership, it’s time to get the recognition you deserve. Submissions close October 3rd. SUBMIT NOW 
|
|
| By Gabrielle Masson Lykos CEO and founder Amy Emerson is stepping down, with Chief Operating Officer Michael Mullette taking over the top spot on an interim basis. |
|
|
|
By James Waldron,Eric Sagonowsky Zenas Biopharma has set out ambitions for a $200 million IPO to fund further studies of its Bristol Myers Squibb-partnered bifunctional antibody in an array of autoimmune indications. Meanwhile, cancer-focused biotech Bicara is seeking to land a similar haul to fund its own bifunctional antibody. |
By Kevin Dunleavy Iterum’s sulopenem, which was initially rejected by the US regulator in 2021 as a treatment for uncomplicated urinary tract infections, is back for another swing, with a target decision date set for October 25. On Monday, an FDA advisory committee will put sulopenem under its microscope, fleshing out concerns that “inappropriate use” of the treatment could cause antimicrobial resistance, according to an FDA briefing document. |
Sponsored by Fierce Biotech Summit Join Fierce Biotech Editors at Fierce Biotech Summit on Sept. 30-Oct.1 in Boston to learn, connect, and innovate with your industry peers. |
|
September 9-12, 2024 | Philadelphia, PA Join us at Digital Pharma East, the leading event for digital innovation in the pharmaceutical industry. Dive into key topics including Digital Marketing, Data & Analytics, and Patient Engagement. Learn from industry experts, network with peers, and explore cutting-edge strategies to drive your digital initiatives forward. Only 1 WEEK LEFT to Join us in Philadelphia! .png)
|
|
By James Waldron In a year that has already seen Connect Biopharma walk away from a Pfizer collaboration and halt its preclinical work, the biotech is now in the process of “significantly reducing” its presence in China. |
By Gabrielle Masson Astellas Pharma has cut the ribbon on a new life sciences center in Massachusetts that will house 400 team members and an incubator lab. |
By James Waldron Psyence Biomedical is paying $500,000 in shares to acquire fellow psilocybin-based biotech Clairvoyant Therapeutics and its phase 2-stage alcohol use disorder (AUD) candidate. |
By Darren Incorvaia,Zoey Becker,Gabrielle Masson Anna Rivkin, Ph.D., was named Foghorn Therapeutics’ first chief business officer as the company continues to build out its leadership team. |
By Darren Incorvaia The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within a couple of months. It also often resists antibiotic treatment, leaving it free to infect the colon and cause diarrhea, nausea, fever and, in severe cases, sepsis and death. |
By Conor Hale A judge said the company didn't live up to the promises made in its 2019 acquisition, over milestone payments linked to the development of Auris' surgical robot. |
By Angus Liu Astellas is closing a gene therapy manufacturing facility in South San Francisco. But across the country, the company opened a new R&D center in Massachusetts. Chinese authorities detained several current or former AstraZeneca employees. And more. |
By Fraiser Kansteiner On Friday, GSK said that its IL-5 antibody Nucala plus inhaled maintenance therapy lowered the annualized rate of moderate or severe exacerbations among chronic obstructive pulmonary disease (COPD) patients for up to 2 years. Nucala is already approved in a range of respiratory conditions, but a COPD nod could present another big opportunity for the drug. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," two experts break down the history of plastics use in the healthcare sector and what it would take for an organization to phase them out. |
|
|---|
|
|
|
Shape the Future of Life Sciences Submissions for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Click to submit your entry for our new 2024 category: AI Innovation. Enter now! 
|
|
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
